Research-only: Recovery / Joints (BPC-157 + TB4)

Public • 2/6/2026

Groups the two most commonly paired research peptides discussed in injury-repair circles; evidence is largely preclinical and not athlete-RCT grade.

← Back Buy stack

Practical pre-check

Deterministic heuristics (stimulants, duplicates, hydration). Not medical advice.

Supplements

Items in this stack

Training load

Unknown load

Need more wearable data

Stimulant estimate

0 mg

Only counts explicit caffeine items

Looks clean

No obvious duplication/stimulant/hydration flags from the heuristic pass.

AI risk assessment

Context: No wearable data

No assessment yet.

Supplements

2 items

BPC-157Low

PLACEHOLDER • Lyophilized • Click to expand

Preclinical tissue-repair signals; limited human evidence.

Buy ingredient →

1mg

Safety / pharmacokinetics

Low

Population: Healthy volunteers

Study type: Registered phase 1 trial (results not posted)

Dose context: — • Duration: See registry

A phase 1 safety/PK study in healthy volunteers was registered; results were not posted and the submission was canceled per later reviews, limiting interpretability.

Citation: ClinicalTrials.gov NCT02637284 — PCO-02 Safety and Pharmacokinetics Trial•https://clinicaltrials.gov/study/NCT02637284

Musculoskeletal healing (preclinical)

Low

Population: Animal injury models (multiple tissues)

Study type: Narrative review of preclinical evidence

Dose context: —

Across animal models, BPC-157 is frequently reported to improve healing-related outcomes (tendon/ligament/muscle/bone and GI injury models), but translation to humans remains unproven.

Citation: Vasireddi et al., (2025) — Emerging Use of BPC-157 in Orthopaedic Sports Medicine (review)•https://pmc.ncbi.nlm.nih.gov/articles/PMC12313605/

Soft tissue healing signals (preclinical)

Low

Population: Animal models (multiple tissues)

Study type: Review (preclinical-focused)

Dose context: —

Multiple preclinical models report improvements in healing-related endpoints; translation to humans remains unproven.

Citation: Cushman et al., Local and Systemic Peptide Therapies for Soft Tissue Healing (2024)•https://pmc.ncbi.nlm.nih.gov/articles/PMC11426299/

TB500 (TB4 / Thymosin Beta-4)Low

PLACEHOLDER • Lyophilized • Click to expand

Wound-healing biology (mostly preclinical); not validated as an athlete recovery protocol.

Buy ingredient →

1mg

Wound healing

Low

Population: Rat full-thickness wound model

Study type: Preclinical animal study

Dose context: —

TB4 accelerated wound healing endpoints in a rat model compared with controls.

Citation: Malinda et al., J Invest Dermatol (1999)•DOI: 10.1046/j.1523-1747.1999.00708.x•https://pubmed.ncbi.nlm.nih.gov/10469335/

Wound healing (reviewed clinical context)

Low

Population: Stasis and pressure ulcer clinical programs

Study type: Review article

Dose context: —

A review summarizes phase 2 wound-healing programs reporting faster healing in those that did heal; note that these are not sports injury RCTs.

Citation: Treadwell et al., Ann N Y Acad Sci (2012) — The regenerative peptide thymosin β4 accelerates the rate of dermal healing•https://pubmed.ncbi.nlm.nih.gov/23050815/

Wound healing (clinical development)

Low

Population: Patients with venous stasis ulcers

Study type: Registered phase 2 trial (TB4 gel)

Dose context: — • Duration: Up to 84 days (per registry)

TB4 gel has been studied in venous stasis ulcer indications; registry evidence supports clinical testing, though effect sizes depend on the specific trial and endpoint reporting.

Citation: ClinicalTrials.gov NCT00832091 — Thymosin Beta 4 in Venous Stasis Ulcers•https://clinicaltrials.gov/study/NCT00832091